dc.contributor.author |
Eigentler, Thomas |
|
dc.contributor.author |
Garbe, Claus |
|
dc.date.accessioned |
2023-05-12T08:33:15Z |
|
dc.date.available |
2023-05-12T08:33:15Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
0140-6736 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/141002 |
|
dc.language.iso |
en |
en |
dc.publisher |
Elsevier Science Inc |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1016/S0140-6736(22)01654-3 |
|
dc.subject.ddc |
610 |
de_DE |
dc.title |
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20230202000000_01150 |
|
utue.publikation.seiten |
1117-1129 |
de_DE |
utue.personen.roh |
Zimmer, Lisa |
|
utue.personen.roh |
Livingstone, Elisabeth |
|
utue.personen.roh |
Hassel, Jessica C. |
|
utue.personen.roh |
Fluck, Michael |
|
utue.personen.roh |
Eigentler, Thomas |
|
utue.personen.roh |
Loquai, Carmen |
|
utue.personen.roh |
Haferkamp, Sebastian |
|
utue.personen.roh |
Gutzmer, Ralf |
|
utue.personen.roh |
Meier, Friedegund |
|
utue.personen.roh |
Mohr, Peter |
|
utue.personen.roh |
Hauschild, Axel |
|
utue.personen.roh |
Schilling, Bastian |
|
utue.personen.roh |
Menzer, Christian |
|
utue.personen.roh |
Kieker, Felix |
|
utue.personen.roh |
Dippel, Edgar |
|
utue.personen.roh |
Rosch, Alexander |
|
utue.personen.roh |
Simon, Jan-Christoph |
|
utue.personen.roh |
Conrad, Beate |
|
utue.personen.roh |
Korner, Silvia |
|
utue.personen.roh |
Windemuth-Kieselbach, Christine |
|
utue.personen.roh |
Schwarz, Leonora |
|
utue.personen.roh |
Garbe, Claus |
|
utue.personen.roh |
Becker, Juergen C. |
|
utue.personen.roh |
Schadendorf, Dirk |
|
dcterms.isPartOf.ZSTitelID |
Lancet |
de_DE |
dcterms.isPartOf.ZS-Issue |
10358 |
de_DE |
dcterms.isPartOf.ZS-Volume |
400 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
|